secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950103-24-012201
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q2 net loss widens to $58.8M; pivots to PRGN-2012 with BLA submission planned H2 2024
--------------------------------------------------------------------------------

- Q2 2024 net loss of $58.8M ($0.23/share) vs $20.3M loss a year ago; includes impairment charge of $32.9M.
- Total revenues fell 59% YoY to approx $0.8M; R&D expenses rose 32% on severance and PRGN-2012 trial costs.
- Strategic reprioritization focuses on PRGN-2012 BLA submission under accelerated path H2 2024; workforce reduced >20%.
- Appointed Phil Tennant as CCO for potential PRGN-2012 commercial launch; raised $31.4M net in August public offering.
- Cash runway expected into early 2025; ActoBio subsidiary shut down, IP portfolio available for sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324012201/0000950103-24-012201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324012201/dp216654_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-012201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer